Research Use Only / Third-Party Analytical Testing / Per-Batch Documentation / Materials Shipped from the USA
Search Account 0 Cart
BPC-157 Liquid Spray research material
Liquid Spray · Research materialHelio®
Helio / Materials / Recovery
Recovery Research

BPC-157 Liquid Spray

This product supplies BPC-157 as a pre-formulated liquid spray, a convenient intranasal/liquid format for research applications that benefit from a ready-to-use solution rather than lyophilized powder requiring reconstitution. BPC-157 is a synthetic pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with molecular formula C62H98N16O22, molecular weight near 1419.5 g/mol, CAS 137525-51-0 and PubChem CID 9941957.

Derived from a protein found in gastric juice, BPC-157 has been examined across tendon, ligament, muscle, bone and mucosal injury models, with proposed angiogenic (VEGFR2) and nitric-oxide-mediated mechanisms. The liquid spray format is provided for laboratory research handling and stability studies. This material is Research Use Only and is not for human or veterinary use.

Identification
  • MaterialBPC-157 Liquid Spray
  • Research AreaRecovery
  • PresentationLiquid Spray
  • Available SizesSpray
  • CAS Number137525-51-0
  • Molecular FormulaC62H98N16O22
  • Molecular Weight1419.5 g/mol
  • TypeSynthetic pentadecapeptide
  • Receptor / TargetNo single defined receptor; investigated via VEGFR2 and nitric oxide (NO) / eNOS-Akt signaling in preclinical models
  • PubChem CID9941957 →
Amino Acid Sequence

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)

Analytical Data
  • Purity (HPLC)≥99%
  • Identity (MS)Confirmed to specification
  • TestingAccredited (ISO 17025) third-party laboratory
  • DocumentationPer-batch COA →
From$89.95

Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.

Key Characteristics
Molecular FormulaC62H98N16O22
Molecular Weight~1419.5 g/mol
CAS Number137525-51-0
PubChem CID9941957
StructureLinear synthetic pentadecapeptide (15 amino acids)
Receptor / TargetNo defined receptor; studied via VEGFR2 and NO/eNOS-Akt angiogenic signaling
FormLiquid spray (pre-formulated solution)
SolubilityFully solubilized in aqueous carrier
StorageRefrigerate at 4°C and protect from light; avoid heat and repeated temperature cycling
StabilityReported aqueous and acid stability; liquid format best kept cold and light-protected
Research Context
AngiogenesisStudied for VEGF up-regulation and vessel formation via VEGFR2 signaling.
Tendon & ligament repairExamined in tendon and ligament injury models for fibroblast and collagen endpoints.
Mucosal & nasal tissueLiquid/intranasal formats are of interest for mucosal and delivery-focused research.
Nitric oxide signalingExplored for NO / eNOS-Akt cytoprotective interactions.
Muscle & soft-tissue healingAssessed in crush-injury and soft-tissue models.
Research Findings

Preclinical studies report BPC-157 promotes angiogenesis and connective-tissue repair across multiple rodent injury models, with vascular and nitric-oxide pathways as recurring mechanistic themes. Liquid and mucosal formats additionally support research into peptide stability and delivery.

All available efficacy data are from animal and in-vitro work; human efficacy, absorption via any route, and safety are not established. This liquid spray is a research material only.

History

BPC-157 was derived in the 1990s from Body Protection Compound, a peptide fraction isolated from human gastric juice, and has been characterized in an extensive experimental literature (also referenced as PL 14736). It remains an investigational, unapproved compound for laboratory research only.

References
  1. Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Current Pharmaceutical Design. 2014;20(7):1121-1125.
  2. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780.
  3. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632.
  4. Brcic L, Brcic I, Staresinic M, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology. 2009;60(Suppl 7):191-196.

View compound profile on NIH PubChem →

Cited literature refers to laboratory and preclinical research. BPC-157 Liquid Spray is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.

Why researchers choose Helio
99%+ PurityHPLC-verified every batch
Accredited TestingIndependent ISO 17025 laboratory
Per-Batch COADocumentation tied to your lot
Made in the USADiscreet, protected shipping
Related

More in Recovery

View area →